| 岳红,张天丽,桑慧,刘平平,陈烜.依达拉奉右崁醇治疗时机对急性脑梗死溶栓患者疗效及安全性的影响.[J].中南医学科学杂志.,2025,(6):1031-1033, 1072. |
| 依达拉奉右崁醇治疗时机对急性脑梗死溶栓患者疗效及安全性的影响 |
| Influences of timing on efficacy and safety of edaravone dexborneol treatment in acute cerebral infarction patients undergoing thrombolysis |
| 投稿时间：2024-06-07 修订日期：2025-06-25 |
| DOI：10.15972/j.cnki.43-1509/r.2025.06.022 |
| 中文关键词: ACI 溶栓 依达拉奉右崁醇 治疗时机 |
| 英文关键词:ACI thrombolysis edaravone dexborneol treatment timing |
| 基金项目:山西省卫生健康委科研课题(2021028) |
|
| 摘要点击次数: 47 |
| 全文下载次数: 21 |
| 中文摘要: |
| 目的分析依达拉奉右崁醇治疗时机对急性脑梗死(ACI)溶栓患者疗效及安全性的影响。 方法选取102例ACI患者,随机均分为早期组(溶栓后立即使用依达拉奉右崁醇)和晚期组(溶栓后24 h使用依达拉奉右崁醇)。比较两组炎症指标、氧化应激指标、临床疗效、美国国立卫生研究院卒中量表(NIHSS)评分、改良Rankin量表(mRS)评分、不良反应等情况。 结果与治疗前比较,两组治疗后超氧化物歧化酶(SOD)升高,超敏C反应蛋白(hs-CRP)、白细胞介素-6(IL-6)、丙二醛(MDA)、活性氧(ROS)、NIHSS、mRS评分均降低；且治疗后早期组hs-CRP、IL-6、MDA、ROS、mRS评分低于晚期组(P＜0.05)。早期组总有效率高于晚期组(P＜0.05)两组不良反应发生率和死亡率比较,差异无显著性(P＞0.05)。 结论依达拉奉右崁醇早期治疗ACI疗效显著且安全性良好,支持临床优先选择早期用药方案。 |
| 英文摘要: |
| AimTo analyze the influences of timing on efficacy and safety of edaravone dexborneol treatment in acute cerebral infarction (ACI) patients undergoing thrombolysis. MethodsA total of 102 ACI patients were randomly divided into an early group (edaravone dexborneol treatment immediately after thrombolysis) and a late group (edaravone dexborneol treatment 24 h after thrombolysis). Inflammatory and oxidative stress markers, clinical efficacy, national institutes of health stroke scale (NIHSS) scores, modified Rankin scale (mRS) scores, and adverse reactions were compared. ResultsCompared with the pretreatment levels, both groups showed increased superoxide dismutase (SOD) and decreased high-sensitivity C-reactive protein (hs-CRP), interleukin-6 (IL-6), malondialdehyde (MDA), reactive oxygen species (ROS), NIHSS, and mRS scores after treatment. The early group had lower hs-CRP, IL-6, MDA, ROS, and mRS scores than the late group (P＜0.05). The early group also exhibited higher total efficacy (P＜0.05), while no significant differences were observed in adverse reaction rates or mortality (P＞0.05). ConclusionEarly treatment with edaravone dexborneol significantly improves efficacy without compromising safety in ACI patients, supporting its priority in clinical practice. |
| 查看全文 查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|